Alport Syndrome Clinical Trials and Treatments

Alport Syndrome is caused by mutations in genes that encode type IV collagen, a protein essential for maintaining the structure of basement membranes in the kidneys, ears, and eyes. These mutations lead to progressive kidney disease characterized by hematuria (blood in the urine), proteinuria (protein in the urine), and eventual kidney failure. The condition follows three inheritance patterns.

The most common symptoms of Alport Syndrome include Blood in urine, which may be visible or detected only in tests, Protein in urine, Progressive high blood pressure, Sensorineural hearing loss, often starting with high frequencies, Progressive vision loss and eye pain, among others. Estimates vary widely. MedlinePlus Genetics puts it at about 1 in 50,000 newborns, and a 2021 review in the Journal of the American Society of Nephrology notes reported figures from 1 in 5,000 to 1 in 53,000. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Alport Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Alport Syndrome is pushing beyond traditional ACE inhibitors and ARBs toward therapies that target the underlying collagen defect and the TGF-beta signaling pathways that drive kidney damage. Combination strategies that layer multiple protective mechanisms together are showing promise in trials, and researchers are using biomarkers to identify which patients will benefit most from specific approaches.

As of October 21, 2026, no current FDA drug label names Alport Syndrome as a condition the drug treats.

Alport Syndrome is caused by variants in the COL4A5, COL4A3 and COL4A4 genes. About two-thirds of cases are X-linked COL4A5; roughly 15% are autosomal recessive COL4A3/COL4A4.

It follows X-linked (COL4A5) or autosomal recessive/dominant (COL4A3, COL4A4) inheritance. Estimates vary widely. MedlinePlus Genetics puts it at about 1 in 50,000 newborns, and a 2021 review in the Journal of the American Society of Nephrology notes reported figures from 1 in 5,000 to 1 in 53,000. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Alport Syndrome looks at the COL4A5, COL4A3 and COL4A4 genes. About two-thirds of cases are X-linked COL4A5; roughly 15% are autosomal recessive COL4A3/COL4A4.

It follows X-linked (COL4A5) or autosomal recessive/dominant (COL4A3, COL4A4) inheritance.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Alport Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Alport Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.